Leerink Swann Lowers Price Target On Vivus To $9-$11

Symbols: VVUS
Share

Leerink Swann lowers its price target on Vivus (Nasdaq: VVUS) from $11-$13 to $9-$11.

Leerink lowered the price target due to potential safety issues with Vivus' late-stage diet drug Qnexa.


 
 
< Previous
Black And Decker and Avis Up As US Stocks Rise (BDK, SWK, HGSI, CAR, F, CIT)
Next >
FBR Capital Upgrades Gaylord Entertainment To Market Perform
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust

Special Offers:
Quick Cash Advance